Long Term Results and Complications After Epistaxis Treatment

Langzeitresultate Und Komplikationen Nach Einer Epistaxisbehandlung

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02127554

Enrollment

591

Registered

2014-04-30

Start date

2014-01-31

Completion date

2015-12-31

Last updated

2015-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nosebleed (Epistaxis) - Posterior or Anterior

Brief summary

The aim of this study is to find the most agreeable and in the long term most efficient treatment for epistaxis.

Detailed description

In the general population epistaxis occurs quite frequently. Approximately 60% of persons will be affected once in their lifetime, and 6% thereof will seek medical advice. Thereby anterior and posterior epistaxis are discerned. Anterior epistaxis is usually located at the Locus Kisselbachii, while posterior bleeds are found further back in the nose. There, most bleeds will originate from the A. sphenopalatina or the A. ethmoidalis. Different treatment modalities exist. Anterior epistaxis are usually easier to treat than posterior ones. The aim of this study is to find the most efficient treatment. This involves the assessment of long term results and potential sequelae. Existing data will be complemented with information about recurrences and complications. The question is: Which treatment method leads to the least numbers of recurrences in the long term with the fewest long term sequelae? Secondly, the most agreeable, least painful treatment method is to be identified. Therefore we will send out questionnaires to patients that were treated between March 29, 2007 and April 1st, 2008 at the Zurich University Hospital.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

14 Years to 80 Years

Healthy volunteers

Inclusion criteria

All patients treated during the study period with known address and who did not decease in the meantime.

Exclusion criteria

Insufficiently filled out questionnaires; Obvious lack of ability to remember (as tested by control questions); Known mental disability

Design outcomes

Primary

Measure	Time frame
Number of patients without recurrence	Up to 8 years post-treatment

Secondary

Measure	Time frame
Discomfort caused by treatment	Up to 1 day post-treatment

Other

Measure	Time frame
Number of complications due to treatment	Up to 8 years post-treatment
Sequelae due to treatment	Up to 8 years post-treatment

Countries

Switzerland

Outcome results